Clinical Trial Update: CART-19 Cells For R/R B-ALL [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for CART-19 cell therapy in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) across Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• CART-19 (CD19-targeted chimeric antigen receptor T-cell therapy)

Snippet

Sponsor: Fujian Medical University | Conditions: Relapsed/Refractory B-cell ALL | Phase 2, Phase 3 | Status: UNKNOWN